

ANUH PHARMA LTD.
CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018
Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2019

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended 30/06/2019	3 months ended 31/03/2019	3 months ended 30/06/2018	12 months ended 31/03/2019
		Unaudited	Audited	Unaudited	Audited
(1)	(2)	(3)	(4)	(5)	(6)
I.	Revenue from operations	8,489.43	8,304.94	8,025.27	32,066.43
II.	Other income	125.64	84.23	114.34	470.19
III.	Total Revenue (I + II)	8,615.07	8,389.17	8,139.61	32,536.62
IV.	Expenses:				
	Cost of materials consumed	5,889.60	6,156.63	6,414.39	24,548.95
	Purchases of Stock-in-Trade	89.84	-	-	366.96
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	664.08	197.96	(270.25)	(621.95)
	Employee benefits expense	312.38	265.32	235.28	1,014.03
	Finance costs	7.93	6.68	0.77	17.10
	Depreciation and amortization expense	91.98	51.72	35.22	166.22
	Other expenses	761.68	906.79	954.86	3,805.19
	Total expenses (IV)	7,817.49	7,585.10	7,370.27	29,296.50
V.	Profit / (Loss) before exceptional and items and tax (III - IV)	797.58	804.07	769.34	3,240.12
VI.	Exceptional items	-	-	-	-
VII.	Profit / (Loss) before tax (V - VI)	797.58	804.07	769.34	3,240.12
VIII	Tax expense:				
	(1) Current tax	214.00	240.40	212.80	879.00
	(2) Deferred tax	(3.79)	32.27	(13.19)	24.53
		210.21	272.67	199.61	903.53
IX	Profit/(Loss) after Tax (VII-VIII)	587.37	531.40	569.73	2,336.59
X	Other Comprehensive Income (net of Tax)				
	(i) Items that will not be reclassified to profit or loss	(7.61)	10.34	(0.03)	(1.38)
	(ii) Items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income (net of Tax)	(7.61)	10.34	(0.03)	(1.38)
XI	Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	579.76	541.74	569.70	2,335.21
	Paid up Equity Share Capital (Face value ₹ 5/- each)	1,252.80	1,252.80	1,252.80	1,252.80
	Other Equity (excluding revaluation reserves)				15,207.48
XII	Earnings per equity share (Non annualised) (In Rs.)				
	(1) Basic	2.34	2.12	2.27	9.33
	(2) Diluted	2.34	2.12	2.27	9.33

See accompanying notes to the financial results



1. The results of the quarter ended June 30,2019 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 07, 2019.

2. The Company has adopted Ind AS 116 "Leases" effective April 01, 2019 as notified by the Ministry of Corporate Affairs (MCA) and applied the Standard to its leases. The impact of adoption of Ind AS 116 on the profit for the quarter is not material.

3. The figures for the quarter ended March 31, 2019 is balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year.

4. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

5. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Limited



Ritesh B. Shah
Whole Time Director & CEO
(DIN: 02496729)



Place : Mumbai

Dated : August 07, 2019

REVIEW REPORT TO THE BOARD OF DIRECTORS OF
ANUH PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Anuh Pharma Limited** ("the Company") for the quarter ended 30th June, 2019 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation'), read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For JAYANTILAL THAKKAR & CO.
CHARTERED ACCOUNTANTS
(FIRM REG. NO. 104133W)



V. A. Merchant

VIRAL A. MERCHANT
PARTNER

MEMBERSHIP NO. 116279
UDIN: 19116279AAAACF6547

PLACE: Mumbai
DATE: 7th August, 2019